{
  "id": "6026dc481cb411341a0000d0",
  "type": "list",
  "question": "List 4 monoclonal antibodies in development for the prevention of migraine.",
  "ideal_answer": "Four monoclonal antibodies targeting either the CGRP ligand or receptor are being studied for migraine prevention: ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab)",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28644160"
  ],
  "snippets": [
    {
      "text": "Currently, 4 monoclonal antibodies targeting either the CGRP ligand or receptor are being studied for migraine prevention: ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "ALD403, eptinezumab, AMG334, erenumab, LY2951742, galcanezumab, TEV-48125, fremanezumab"
}